JPMorgan Multi-Asset Growth & Income MATE declare first interim dividend of 1.025p per ordinary share

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) have declared the following distribution:

First interim distribution

A first interim distribution of 1.025 pence per ordinary share, for the year ending 28^th February 2022, will be paid on 6^th August 2021 to shareholders on the register at the close of business on 2^nd July 2021. The ex-dividend date will be 1^st July 2021.

For this first interim distribution of the Company’s year ending 28^th February 2022, JPMorgan Multi-Asset Growth & Income has elected not to ‘stream’ part of the distribution payment and therefore the whole of the 1.025 pence will be designated as a dividend to shareholders.

Click to view all articles for the EPIC: mate
Or click to view the full company profile:
JPMorgan Multi-Asset Growth & Income plc

Procter & Gamble names L V Vaidyanathan as CEO for India operations

21st April 2022

Global FMCG firm Procter & Gamble announced the appointment of L V Vaidyanathan as the Chief Executive Officer for its operations in India from July 1, 2022. Vaidyanathan will take over from Madhusudan Gopalan, who will

AbbVie presents positive investigational Navitoclax combination data in Phase 2 study

14th April 2022

AbbVie (NYSE: ABBV) announced new data from a Phase 2 trial of navitoclax in combination with ruxolitinib in patients with myelofibrosis. The results were presented at the American Association for Cancer Research annual meeting (AACR 2022,

Analog Devices sees growth accelerating

8th April 2022

Analog Devices expects annual revenue growth to average 7% to 10% over the next five years, the chip maker told analysts at a meeting Tuesday morning at the company’s headquarters near Boston. As the name implies, Analog

US FDA approves new Bristol Myers cancer immunotherapy

28th March 2022

Bristol Myers Squibb Co said on Friday that U.S. regulators approved the first drug in a new class of cancer immunotherapies as an initial treatment for advanced melanoma, the deadliest form of skin cancer. The company

Imugene collaborates with Merck for gastric cancer clinical trial

16th March 2022

Imugene (IMU) has joined forces with Merck & Co for a new clinical trial collaboration and supply agreement for the treatment of gastric cancer. Imugene and MSD, a trade name of Merck, will evaluate the safety

Roche steps up with a free supply of antibiotics for Ukraine as drug donations begin to flow

7th March 2022

Switzerland-based Roche is stepping up to the crisis in Ukraine today with plans to donate 150,000 packages of Rocephin, an essential antibiotic used to treat bacterial infections, to the hard-pressed citizenry. The pharma major — which

Analog Devices to create 250 jobs as it invests €100m in Limerick facility

4th March 2022

Semiconductor company Analog Devices is to create 250 new jobs as it invests €100 million over the next three years in ADI Catalyst, a 100,000sq ft facility for innovation and collaboration located at its campus in the Raheen

‘Risk Assets will rally’ says JPMorgan Multi Asset Growth & Income fund

2nd March 2022

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) published their commentary for January 2022. Month in review The trust delivered a negative return on net assets in January. Our equity allocation contributed negatively to overall performance as equity markets declined, driven

Analog Devices eyes bigger role in 5G base stations with Radio SoC

25th February 2022

Telecom giants are buying wireless base stations by the thousands to install in new 5G networks in the U.S., China, Europe, and other regions around the world. But they are still in the early stages of

Multi asset income trust balances yield, diversified risk and return (LON:MATE)

15th February 2022

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) has declared its ten largest investments in % of total assets as at 31st January 2022: US 10YR (New Style) Bond Commodity (Future) 14.1% Infrastructure Investments Fund 8.2% JPMorgan Global

Bristol Myers Squibb reports 9% full-year 2021 revenue growth

14th February 2022

Bristol Myers Squibb (BMS) has reported a 9% growth in revenue to $46.4bn for full-year 2021 compared with $42.52 in 2020. During the year, net product sales surged to $45.1bn from $41.3 in 2020. Furthermore, the

Analog Devices expands production, will hire hundreds at chip factories near Portland

10th February 2022

Analog Devices Inc., which has two chip factories in the Portland area, says it’s increasing production at both of them and adding staff in response to soaring demand. The Massachusetts-based company makes chips for industrial, automotive,

Multi-asset income investing: MATE plc delivers positive return on net assets

10th February 2022

JPMorgan Multi-Asset Growth & Income plc (LON:MATE) published their commentary for December 2021. Month in review The trust delivered a positive return on net assets in December. Our bespoke equity sleeve – which is run by the JPMAM International Equity Group

Procter & Gamble-owned Pantene partners with impressive female collective

31st January 2022

THE WHAT? Procter & Gamble-owned Pantene has teamed up with ‘impressive, strong, modern, multi-hyphenate women’ to form the new Pantene Conditioner Collective. THE DETAILS Partners of the collective include Chloe Fineman, who features on Saturday Night Live and Dickinson, comedian Meg

Procter & Gamble’s sales jump

24th January 2022

Shoppers shrugged off rising prices last year on products like Pampers diapers and Charmin toilet paper, Procter & Gamble said on Wednesday in announcing a jump in its second-quarter earnings. The consumer goods giant reported that

Abbvie looks to crack the cystic fibrosis code

21st January 2022

When it comes to cystic fibrosis Vertex is the undisputed heavyweight, but this has not stopped other groups from taking it on. Abbvie is the latest challenger, and data due this quarter could give clues about

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

17th January 2022

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development. Bristol Myers Squibb announced on Jan. 10,

Italy to receive 40,000 Merck antiviral drug doses next week

12th January 2022

Italy will receive around 40,000 doses of Merck & Co’s (MRK.N) COVID-19 antiviral drug next week, which will add to nearly 12,000 already distributed to hospitals, the special COVID-19 commissioner said on Sunday. “They are intended

Be sure to check our sister interview main ratings news website